NASDAQ
Iterum Therapeutics plc (ITRM) has a free cash flow growth of -65.44% as of Friday, May 29, 2026. This represents a 910.40% decrease compared to its 12-month average of -6.48%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.